ALT Stock Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.33|
|52 Week High||US$17.26|
|52 Week Low||US$3.83|
|1 Month Change||-2.68%|
|3 Month Change||212.94%|
|1 Year Change||13.33%|
|3 Year Change||481.60%|
|5 Year Change||-80.34%|
|Change since IPO||-94.80%|
Recent News & Updates
Altimmune: Several Catalysts In 2 Large Market Indications This Year
Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027. Interim results from the phase 2 MOMENTUM study using pemvidutide for obesity are expected in Q4 of 2022; This will deal with 24-week interim data for weight loss. The global obesity treatment market will reach $15.6 billion by 2024.
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|ALT||US Biotechs||US Market|
Return vs Industry: ALT exceeded the US Biotechs industry which returned -25.9% over the past year.
Return vs Market: ALT exceeded the US Market which returned -13% over the past year.
|ALT Average Weekly Movement||16.6%|
|Biotechs Industry Average Movement||12.8%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.2%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ALT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: ALT's weekly volatility has increased from 11% to 17% over the past year.
About the Company
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune Fundamentals Summary
|ALT fundamental statistics|
Is ALT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALT income statement (TTM)|
|Cost of Revenue||US$81.38m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
|Earnings per share (EPS)||-2.37|
|Net Profit Margin||-2,820.39%|
How did ALT perform over the long term?See historical performance and comparison
Is ALT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALT?
Other financial metrics that can be useful for relative valuation.
|What is ALT's n/a Ratio?|
Price to Book Ratio vs Peers
How does ALT's PB Ratio compare to its peers?
|ALT PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ARCT Arcturus Therapeutics Holdings
VRDN Viridian Therapeutics
ADAP Adaptimmune Therapeutics
Price-To-Book vs Peers: ALT is good value based on its Price-To-Book Ratio (2.9x) compared to the peer average (3.5x).
Price to Earnings Ratio vs Industry
How does ALT's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: ALT is expensive based on its Price-To-Book Ratio (2.9x) compared to the US Biotechs industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is ALT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.9x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate ALT's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ALT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALT's revenue (86.4% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: ALT's revenue (86.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Altimmune performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALT is currently unprofitable.
Growing Profit Margin: ALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.
Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).
Return on Equity
High ROE: ALT has a negative Return on Equity (-54.99%), as it is currently unprofitable.
Discover strong past performing companies
How is Altimmune's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALT's short term assets ($191.1M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: ALT's short term assets ($191.1M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: ALT is debt free.
Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 14.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALT has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 45% each year.
Discover healthy companies
What is Altimmune current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vipin Garg (64 yo)
Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...
CEO Compensation Analysis
Compensation vs Market: Vipin's total compensation ($USD2.63M) is about average for companies of similar size in the US market ($USD2.66M).
Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.
Experienced Management: ALT's management team is considered experienced (3.9 years average tenure).
Experienced Board: ALT's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ALT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.
Altimmune, Inc.'s employee growth, exchange listings and data sources
- Name: Altimmune, Inc.
- Ticker: ALT
- Exchange: NasdaqGM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$529.123m
- Shares outstanding: 42.91m
- Website: https://altimmune.com
Number of Employees
- Altimmune, Inc.
- 910 Clopper Road
- Suite 201S
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.